Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOUSAB TABBAA

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1184642050
CMS profile
325267
Location
WESTLAKE, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$28,989.37

53 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOUSAB TABBAA

NPI 1184642050 · CMS profile ID 325267

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

WESTLAKE, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184642050?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOUSAB TABBAA, NPI 1184642050, CMS profile ID 325267. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184642050?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MOUSAB TABBAA, NPI 1184642050, CMS profile ID 325267. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184642050?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MOUSAB TABBAA, NPI 1184642050, CMS profile ID 325267, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1184642050?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

53 matching records · $28,989.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 53 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–53 of 53.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $124.9201/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106193352 CMS
ABBVIE INC. $24.0001/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106193350 CMS
Daiichi Sankyo Inc. $17.5901/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089488430 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $15,261.59 17
PY2020 $4,672.26 9
PY2021 $588.72 17
PY2022 $1,971.53 29
PY2023 $16,644.75 32
PY2024 $28,989.37 53
PY2025 $68,106.08 16

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,598.11 2
PY2025 Principal investigator $495,552.41 139
PY2024 Principal investigator $582,875.82 97
PY2023 Principal investigator $176,547.79 31
PY2021 Principal investigator $16,200.00 3
PY2020 Principal investigator $13,650.00 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

141 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 F. Hoffmann-La Roche AG $4,331.00 12/19/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607896
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 12/17/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780212
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 12/17/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780232
Principal investigator 1 Boehringer Ingelheim International GmbH $839.50 12/17/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780234
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 12/17/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780236
Principal investigator 1 Genentech, Inc. $1,500.00 12/16/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LL
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211664303
Principal investigator 1 Genentech, Inc. $6,500.00 12/16/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LL
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211664312
Principal investigator 1 Genentech, Inc. $1,215.00 12/16/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LL
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211664320
Principal investigator 1 F. Hoffmann-La Roche AG $276.00 12/11/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607888
Principal investigator 1 F. Hoffmann-La Roche AG $9,777.30 12/11/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607892
Principal investigator 1 Madrigal Pharmaceuticals $2,018.25 12/11/2025 Non-covered Recipient Entity
CRIOH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254094
Principal investigator 1 Madrigal Pharmaceuticals $3,037.50 12/11/2025 Non-covered Recipient Entity
CRIOH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254098
Principal investigator 1 Madrigal Pharmaceuticals $400.00 12/11/2025 Non-covered Recipient Entity
CRIOH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254102
Principal investigator 1 Genentech, Inc. $5,371.00 11/25/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608017
Principal investigator 1 Genentech, Inc. $2,651.00 11/25/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608020
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 11/19/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780210
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 11/19/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780228
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 11/19/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780230
Principal investigator 1 Genentech, Inc. $2,168.00 11/12/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211664390
Principal investigator 1 Genentech, Inc. $2,579.00 11/07/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608025
Principal investigator 1 Genentech, Inc. $169.00 11/06/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211664371
Principal investigator 1 Genentech, Inc. $211.00 11/06/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211664375
Principal investigator 1 Genentech, Inc. $1,135.00 11/06/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211664383
Principal investigator 1 Genentech, Inc. $500.00 11/06/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211664386
Principal investigator 1 Genentech, Inc. $230.00 11/06/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211664393
Principal investigator 1 Genentech, Inc. $5,320.00 10/29/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607988
Principal investigator 1 Genentech, Inc. $1,000.00 10/29/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608001
Principal investigator 1 Genentech, Inc. $2,120.00 10/29/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608012
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 10/27/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780224
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 10/27/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780226
Principal investigator 1 Madrigal Pharmaceuticals $2,475.23 10/23/2025 Non-covered Recipient Entity
CRIOH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252039
Principal investigator 1 Boehringer Ingelheim International GmbH $9,275.00 10/16/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780206
Principal investigator 1 Boehringer Ingelheim International GmbH $959.00 10/15/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780208
Principal investigator 1 Genentech, Inc. $5,597.00 10/09/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608009
Principal investigator 1 Madrigal Pharmaceuticals $8,618.40 10/09/2025 Non-covered Recipient Entity
CRIOH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251473
Principal investigator 1 Genentech, Inc. $10,173.36 10/03/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607992
Principal investigator 1 Genentech, Inc. $2,358.00 10/03/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607995
Principal investigator 1 Genentech, Inc. $117.00 10/03/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608005
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 09/24/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780202
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/24/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780204
Principal investigator 1 F. Hoffmann-La Roche AG $296.00 09/23/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607869
Principal investigator 1 F. Hoffmann-La Roche AG $2,651.00 09/18/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607865
Principal investigator 1 F. Hoffmann-La Roche AG $3,116.00 09/12/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607884
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 08/26/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780198
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 08/26/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780200
Principal investigator 1 F. Hoffmann-La Roche AG $9,877.00 08/26/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607880
Principal investigator 1 Madrigal Pharmaceuticals $5,085.12 08/14/2025 Non-covered Recipient Entity
CRIOH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248325
Principal investigator 1 Madrigal Pharmaceuticals $50.00 08/14/2025 Non-covered Recipient Entity
CRIOH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248330
Principal investigator 1 Madrigal Pharmaceuticals $16,875.00 08/14/2025 Non-covered Recipient Entity
CRIOH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248333
Principal investigator 1 Madrigal Pharmaceuticals $540.00 08/14/2025 Non-covered Recipient Entity
CRIOH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248337
Principal investigator 1 Genentech, Inc. $19,144.35 08/01/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211664352
Principal investigator 1 F. Hoffmann-La Roche AG $6,412.00 07/31/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607858
Principal investigator 1 F. Hoffmann-La Roche AG $2,579.00 07/31/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607876
Principal investigator 1 F. Hoffmann-La Roche AG $16,243.00 07/10/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607862
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,325.00 07/09/2025 Non-covered Recipient Entity
CRIOH, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220811526
Principal investigator 1 Madrigal Pharmaceuticals $270.00 07/04/2025 Non-covered Recipient Entity
CRIOH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246378
Principal investigator 1 Madrigal Pharmaceuticals $14,242.50 07/04/2025 Non-covered Recipient Entity
CRIOH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246383
Recipient Eli Lilly and Company $740.90 06/24/2025 Covered Recipient Physician A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187871093
Recipient Eli Lilly and Company $857.21 06/24/2025 Covered Recipient Physician A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE AND OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187876947
Principal investigator 1 Madrigal Pharmaceuticals $2,475.23 06/24/2025 Non-covered Recipient Entity
CRIOH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246156
Principal investigator 1 Genentech, Inc. $2,847.00 06/19/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607941
Principal investigator 1 Eli Lilly and Company $273.88 06/11/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE AND OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187881672
Principal investigator 1 Eli Lilly and Company $273.88 06/10/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187881772
Principal investigator 1 Genentech, Inc. $9,543.75 06/03/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211664343
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 05/27/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780188
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 05/27/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780190
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 05/27/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780192
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 05/27/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780194
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 05/27/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780196
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 05/27/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780214
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 05/27/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780216
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 05/27/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780218
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 05/27/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780220
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 05/27/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780222
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,625.00 05/27/2025 Non-covered Recipient Entity
CRIOH, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220811522
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $770.00 05/27/2025 Non-covered Recipient Entity
CRIOH, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220811524
Principal investigator 1 Genentech, Inc. $3,497.00 05/27/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607945
Principal investigator 1 Genentech, Inc. $3,360.00 05/27/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607980
Principal investigator 1 Madrigal Pharmaceuticals $9,272.48 05/15/2025 Non-covered Recipient Entity
CRIOH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243892
Principal investigator 1 Madrigal Pharmaceuticals $3,887.50 05/15/2025 Non-covered Recipient Entity
CRIOH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243896
Principal investigator 1 Madrigal Pharmaceuticals $50.00 05/15/2025 Non-covered Recipient Entity
CRIOH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243900
Principal investigator 1 Genentech, Inc. $18,112.00 05/08/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607932
Principal investigator 1 Genentech, Inc. $3,116.00 05/08/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607975
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 05/08/2025 Non-covered Recipient Entity
CRIOH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192126161
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 05/08/2025 Non-covered Recipient Entity
CRIOH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192126174
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 05/08/2025 Non-covered Recipient Entity
CRIOH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192126182
Principal investigator 1 GlaxoSmithKline, LLC. $250.00 05/08/2025 Non-covered Recipient Entity
CRIOH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192126187
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 05/08/2025 Non-covered Recipient Entity
CRIOH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192126193
Principal investigator 1 GlaxoSmithKline, LLC. $250.00 05/08/2025 Non-covered Recipient Entity
CRIOH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192131092
Principal investigator 1 GlaxoSmithKline, LLC. $175.00 05/08/2025 Non-covered Recipient Entity
CRIOH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192131097
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 05/08/2025 Non-covered Recipient Entity
CRIOH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192131112
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 05/08/2025 Non-covered Recipient Entity
CRIOH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192131117
Principal investigator 1 Madrigal Pharmaceuticals $7,049.75 04/28/2025 Non-covered Recipient Entity
CRIOH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242840
Principal investigator 1 Madrigal Pharmaceuticals $50.00 04/28/2025 Non-covered Recipient Entity
CRIOH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242844
Principal investigator 1 Genentech, Inc. $10,000.00 04/23/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607921
Principal investigator 1 Genentech, Inc. $2,200.00 04/23/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607925
Principal investigator 1 Genentech, Inc. $1,524.00 04/23/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607953
Principal investigator 1 Genentech, Inc. $414.00 04/23/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607984
Principal investigator 1 Genentech, Inc. $396.00 04/22/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607948
Principal investigator 1 Genentech, Inc. $9,660.00 04/22/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607961
Principal investigator 1 Genentech, Inc. $9,877.00 04/15/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607935
Principal investigator 1 Genentech, Inc. $2,443.00 03/19/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607909
Principal investigator 1 Boehringer Ingelheim International GmbH $33.71 03/13/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780172
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 03/13/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780174
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 03/13/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780176
Principal investigator 1 Boehringer Ingelheim International GmbH $21.43 03/13/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780178
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 03/13/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780180
Principal investigator 1 Boehringer Ingelheim International GmbH $12.86 03/13/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780182
Principal investigator 1 Boehringer Ingelheim International GmbH $259.00 03/13/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780184
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 03/13/2025 Non-covered Recipient Entity
North Shore Gastroenterology Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780186
Principal investigator 1 Genentech, Inc. $8,253.00 03/06/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607900
Principal investigator 1 Genentech, Inc. $9,777.00 03/06/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607904
Principal investigator 1 Genentech, Inc. $2,198.00 03/06/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607914
Principal investigator 1 Genentech, Inc. $12,428.00 03/06/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607917
Principal investigator 1 Madrigal Pharmaceuticals $10,552.40 03/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF OHIO LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240278
Principal investigator 1 GlaxoSmithKline, LLC. $8,985.48 03/05/2025 Non-covered Recipient Entity
CRIOH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192131105
Principal investigator 1 GlaxoSmithKline, LLC. $907.20 02/26/2025 Non-covered Recipient Entity
CRIOH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192126167
Principal investigator 1 GlaxoSmithKline, LLC. $140.00 02/26/2025 Non-covered Recipient Entity
CRIOH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192131122
Principal investigator 1 Genentech, Inc. $6,816.00 02/18/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607966
Principal investigator 1 AstraZeneca UK Limited $17,254.00 02/12/2025 Non-covered Recipient Entity
CRIOH LLC
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185547675
Principal investigator 1 Madrigal Pharmaceuticals $14,889.84 02/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF OHIO LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239108
Principal investigator 1 Genentech, Inc. $16,886.00 02/03/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211664323
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Clinical Research Institute Of Ohio LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220732682
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Clinical Research Institute Of Ohio LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220732684
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Clinical Research Institute Of Ohio LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220732686
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Clinical Research Institute Of Ohio LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220732688
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Clinical Research Institute Of Ohio LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220732690
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Clinical Research Institute Of Ohio LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220732692
Principal investigator 1 Madrigal Pharmaceuticals $23,220.00 01/30/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF OHIO LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238867
Principal investigator 1 Genentech, Inc. $13,839.00 01/21/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607927
Principal investigator 1 Genentech, Inc. $5,828.00 01/17/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607937
Principal investigator 1 Genentech, Inc. $10,000.00 01/17/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607957
Principal investigator 1 Genentech, Inc. $2,200.00 01/17/2025 Non-covered Recipient Entity
GASTRO INTESTINAL RESEARCH INSTITUTE OF NORTHERN OHIO LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211607971
Principal investigator 1 Madrigal Pharmaceuticals $8,367.50 01/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF OHIO LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238017
Principal investigator 1 Madrigal Pharmaceuticals $4,764.49 01/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF OHIO LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238021
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute Of Ohio LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220732672
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute Of Ohio LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220732674
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute Of Ohio LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220732676
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute Of Ohio LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220732678
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute Of Ohio LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220732680
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute Of Ohio LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220732694